Skip to content

Arbutus Biopharma Corporation ABUS Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Gilead Sciences logo
Gilead SciencesGILD
ALN
Alnylam PharmaceuticalsALNY
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
Lantheus Holdings logo
Lantheus HoldingsLNTH
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$871.14M+32.6%
Enterprise value$848.07M+36.6%
P/E5.4×
P/S4.6×-98.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's preferred stock, shares authorized?
Arbutus Biopharma Corporation (ABUS) reported preferred stock, shares authorized of $1.16M in Q1 2026.
How has Arbutus Biopharma Corporation's preferred stock, shares authorized changed year-over-year?
Arbutus Biopharma Corporation's preferred stock, shares authorized decreased by 0.0% year-over-year, from $1.16M to $1.16M.